ALTSTATION.IO

The Clorox Company (CLX) Stock Analysis

By Nova Skye | AltStation.io | Updated November 01, 2026

Price
$88.00
Change
-0.76%
Market Cap
$10.64B
Avg Volume
2.9M

Company Overview

The Clorox Company is an Oakland, California-based consumer defensive manufacturer founded in 1913 that sells everyday household, personal care, and professional products. The business operates across four segments: Health and Wellness, Household, Lifestyle, and International. Beyond its core bleach and cleaning lines, Clorox owns staple brands including Glad trash bags, Kingsford charcoal, Fresh Step cat litter, Brita filters, Burt’s Bees, and Hidden Valley dressings. It distributes these goods worldwide through mass retailers, grocery stores, warehouse clubs, dollar stores, and direct-to-consumer digital channels.

Within the household and personal products space, Clorox holds a dominant market-leader position built on household name recognition and prime retail shelf placement. Its biggest advantage is brand equity across several distinct non-bleach categories, allowing it to command pricing power over off-brand alternatives. The primary threat comes from lower-cost private-label store brands and large consumer packaged goods conglomerates fighting for the same shelf space. In a defensive sector, maintaining customer loyalty against cheaper generic substitutes is the central battle.

Right now, the company focuses on protecting operating margins across its diversified consumer portfolio while navigating shifting shopper habits. Its multi-brand setup across four segments gives it balance, using steady cleaning and laundry staples to offset cyclical demand in lifestyle or grilling categories. The ongoing challenge is defending market share in grocery and mass retail aisles as price-sensitive consumers weigh branded goods against cheaper private-label options.

Key Financials
Market Cap
$10.64B
Revenue
$6.72B
EBITDA
$1.14B
Gross Margin
42.3%
Profit Margin
8.7%
Revenue Growth
-2.0%
Total Cash
$143.00M
Total Debt
$5.60B
Free Cash Flow
$110.38M


52-Week Price Performance Analysis

Price Statistics
P/E Ratio
18.30
Forward P/E
14.35
Beta
0.57
52-Week High
$128.90
52-Week Low
$79.12
EPS
$4.81
50-Day Avg
$88.60
200-Day Avg
$99.77
Price/Book
118.28
CLX 52-Week Stock Chart
Technical Analysis
CLX trades at $88.00, 29.05% below its $124.03 52-week high and 12.84% above its $77.99 low. The stock sits just 22% of the way from that low to the high, so the broader trend remains weak. Short-term momentum has improved, with gains of 3.33% over five trading days and 11.03% over 20 trading days. The price is 4.03% above its 20-day moving average of $84.59. Near-term support is $79.26, while resistance is $88.67.


Recent News and Developments

Clorox names Fabian Garcia as its next CEO

Garcia will become CEO and join the board on January 5, 2027, succeeding Linda Rendle. The Unilever Personal Care president previously led Revlon and held senior roles at Colgate-Palmolive and Procter & Gamble. Source: The Clorox Company

Zacks downgrades CLX to Strong Sell

Zacks Research cut Clorox from Hold to Strong Sell and projected fiscal 2027 earnings of $5.53 per share. Its estimates call for quarterly EPS of $0.91, $1.30, $1.56 and $1.77 across fiscal 2027. Source: MarketBeat

Earnings estimates rise, but the setup remains weak

Clorox reports fiscal first-quarter results after the November 2 close. Zacks expects revenue of $1.9 billion, up 31%, and EPS of $0.97, up 14.1%, but assigns CLX a Sell rank. Source: Zacks Equity Research



Market Sentiment and Analyst Recommendations

Bull Case
The immediate bull case is improving momentum from a depressed price. CLX has gained 11.03% over the last 20 trading days and now trades 4.03% above its $84.59 moving average. The $96.35 analyst target is above the current $88.00 price, while the top target reaches $154.00. Zacks expects fiscal first-quarter revenue of $1.9 billion, up 31%, and EPS of $0.97, up 14.1%. Fabian Garcia’s appointment as CEO on January 5, 2027 gives investors a clear leadership catalyst after earnings. A buyer here is betting that stronger quarterly results and new leadership can extend the rebound from the $77.99 low.
Bear Case
The core business is not growing, with revenue down 2.0%. Clorox carries $5.60 billion in total debt against only $143.00 million in cash, leaving little balance-sheet cushion. The stock also trades at 18.30 times earnings despite negative revenue growth. Analysts remain cautious: the consensus recommendation is Hold across 17 analysts, and the target range stretches from $74.00 to $154.00. Zacks downgraded CLX from Hold to Strong Sell and projected fiscal 2027 earnings of $5.53 per share. The stock remains 29.05% below its $124.03 technical 52-week high, so the recent rally has not repaired the larger decline.
What to Watch
Clorox reports fiscal first-quarter results after the November 2 close. The key benchmarks are Zacks estimates of $1.9 billion in revenue and $0.97 in EPS, representing expected growth of 31% and 14.1%, respectively. Investors should watch whether the stock can break above the $88.67 30-day high or falls back toward $79.26 support. The $84.59 20-day moving average is another useful threshold because CLX currently trades 4.03% above it. Fabian Garcia becomes CEO and joins the board on January 5, 2027, making the leadership transition another major test. Results strong enough to support targets of $91, $100 and $110 would improve the thesis, while a move toward the $74 analyst low would confirm that the rebound failed.
Analyst Consensus
HOLD

Based on 17 analyst opinions
Low Target
$74.00
Mean Target
$96.35
High Target
$154.00


Earnings and Financial Data

Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
9,200
Earnings & Dividends
Next Earnings
Nov 02, 2026
EPS (Trailing)
$4.81
Dividend Yield
568.0%
Payout Ratio
103.1%

Frequently Asked Questions

Is CLX a good stock to buy?
CLX has positive short-term momentum, but revenue growth is negative 2.0% and the consensus recommendation from 17 analysts is Hold. The takeaway is that the available data supports caution, not a clear buy.
What is CLX’s price target?
The analyst target is $96.35, with estimates ranging from $74.00 to $154.00. The takeaway is that analysts see possible upside from $88.00, but the wide range shows substantial disagreement.
Is CLX stock undervalued?
CLX trades at a P/E ratio of 18.30 and sits 29.05% below its technical 52-week high of $124.03. The takeaway is that the stock is well below its high, but the provided data does not establish that it is undervalued.
What are CLX’s support and resistance levels?
Near-term support is the 30-day low of $79.26, while near-term resistance is the 30-day high of $88.67. The takeaway is that $88.67 is the immediate breakout level and $79.26 is the key downside level.
Does CLX pay a dividend?
The provided data does not include a dividend amount or yield. The takeaway is that no dividend conclusion can be made from the available figures.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated November 01, 2026.